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Abstract
Background: Group A Streptococcus (GAS) strain diversity varies across different regions of the world, according to
low versus high-income countries. These differences may be related to geographic, environmental, socioeconomic,
or host-related factors. However, local factors may also affect strain diversity. We compared the emm types of GAS
isolates from children with and without sore throat in one large urban setting in Brazil.
Methods: Children 3-15 years of age were consecutively recruited from slum and non-slum pediatric outpatient
clinics between April-October, 2008. Throat cultures were performed and data intake forms were completed. GAS
isolates were typed by emm sequencing.
Results: From 2194 children, 254 (12%) GAS isolates were obtained. Of 238 GAS isolates that were emm-typed, 61
unique emm types were identified. Simpson’s diversity index of the emm types was higher among isolates from
slum children [97% (96%-98%)] than those of non-slum children [92% (89%-96%)]. Two emm types (66.0, 12.0) were
more frequently isolated from children with sore throat (p < 0.05), and one emm type (27G.0) demonstrated a
protective effect.
Conclusions: The emm type diversity from children attending slum clinics resembled the emm diversity of low
income countries rather than that of children attending a non-slum clinic in the same city. Local factors, such as
crowding, may enhance the frequency of GAS transmission and horizontal gene transfers that contribute to
increased strain diversity in the slums. GAS vaccine coverage and control of GAS infections will need to take these
local factors and strain differences into consideration.
Background
Group A Streptococcus (Streptococcus pyogenes; GAS)
causes a wide spectrum of diseases, including pharyngi-
tis and pyoderma to more severe diseases such as toxic
shock syndrome, necrotizing fasciitis, glomerulonephritis
and rheumatic heart disease (RHD) [1]. Children are the
major reservoir of GAS [2]. The highest prevalence of
GAS infections and their complications are found in
developing countries [3].
GAS strain typing is frequently used to characterize
the epidemiology and pathogenesis of GAS infections.
The most common target of typing methods is the M
protein, which is a cell surface virulence factor serving
as a target of the immune response to GAS that confers
type-specific resistance. A sequence-based typing system
called emm sequence typing, based on the N-terminus
hypervariable region (5’)o ft h eMp r o t e i ng e n e ,i sn o w
widely used [4]. Many studies have been conducted
using emm typing to show associations of specific strain
types with disease outcomes [5-9]. Information about
geographic emm type distribution can also be used to
assess candidate vaccine coverage [10,11], including that
of a 26-valent vaccine that has recently completed phase
II trials [12].
Epidemiologic studies have revealed that developing
countries have high emm type diversity [13,14], while
high-income countries are more likely to have a limited
number of emm types [15-18]. This pattern was clearly
demonstrated in a recent systematic review of 120 arti-
cles and reports on GAS emm types [19]. It found a
* Correspondence: lwriley@berkeley.edu
6University of California, Berkeley, School of Public Health, USA
Full list of author information is available at the end of the article
Tartof et al. BMC Infectious Diseases 2010, 10:327
http://www.biomedcentral.com/1471-2334/10/327
© 2010 Tartof et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.higher diversity of emm types in Africa and the Pacific
compared to high-income countries, which may be
related to differences in geographic, environmental,
socioeconomic or host factors. However, comparisons
which are made across continents cannot evaluate the
impact of local factors on genotype distribution. In this
study, we compared the emm types of GAS isolates
o b t a i n e df r o mc h i l d r e ni ns l u ma n dw e a l t h yn e i g h b o r -
hoods in the same city, Salvador, Brazil to examine the
influence of urban environmental, demographic, and
socioeconomic factors on diversification of GAS.
Furthermore, we collected isolates from children with
and without sore throat to identify associations of cer-
tain emm types with clinical outcome.
Methods
Study Sites
This study was conducted at three pediatric outpatient
emergency clinics (clinics A, B, and C). Clinical services
at Clinic A and Clinic B are offered free to patients
through the publicly funded Unified Health System
(SUS). These clinics serve primarily low-income
patients. The socioeconomic status and demographic
characteristics (household density, income, education
level of mother and father) of patients seeking care at
Clinic A and Clinic B are similar. Clinic C serves weal-
thier clientele and only those with private insurance.
Clinic B is located 24 km from Clinic C, Clinic A is
located 32 km from Clinic B, and Clinic A is located 11
km to Clinic C. The size of the patient population is
comparable between the three clinics. Each clinic
receives about 5000-6000 children as outpatients each
year.
Patient Recruitment
Patients aged 3-15 years were consecutively recruited
from Clinics A-C from April 17, 2008 to October 31,
2008. Recruitment occurred while patients waited for
their medical evaluation, or immediately following their
appointment. Parents/guardians of children were
approached by a research team member for recruitment
and consent to participate in the study. At this time, a
brief description of the study, risks, benefits, and issues
of confidentiality were provided. Following consent from
parents/guardians and verbal assent from minors, a
trained member of the research team administered a
standardized questionnaire and collected a throat swab
sample of the study participant. All members of the
research team were trained in standardized technique
for both procedures. Institutional Review Board (IRB)
approval was obtained from all hospitals, the Comissão
Nacional de Ética em Pesquisa (Conep)( N a t i o n a l
Bioethics Commission of Brazil), the Comitê de Ética
em Pesquisa-Centro de Pesquisa Gonçalo Moniz -
Fiocruz (Ethics Committee for Research - Fiocruz), and
the University of California, Berkeley Committee for the
Protection of Human Subjects.
Definitions
Slum communities were defined according to the United
Nations Human Settlements Program as human settle-
ment areas that have one or more of the following char-
acteristics: 1) inadequate access to safe water; 2)
inadequate access to sanitation and other infrastructure;
3) poor structural quality of housing; 4) overcrowding;
and 5) insecure residential status [20]. In the neighbor-
hoods served by Clinic A and B, these characteristics
vary at the individual household level. However, what
these slum settlements all have in common is that they
were illegally built on land with unclear tenure status.
The structural quality of housing also varies among resi-
dential units in these slums (red brick houses with
unfinished wall and tile roof; shacks made of discarded
lumber and corrugated tin roof), but the common char-
acteristics are that they were all built with no official
permit.
Cases were defined as those children whose chief
complaint was sore throat. GAS culture-positive sore
throat was defined as a child with a sore throat in
whom GAS was isolated from the throat swab. Controls
were defined as those visiting the clinics for other rea-
sons. Exclusion criteria included use of antibiotics in the
past two weeks, or any illness requiring inpatient hospi-
talization on the day of recruitment. Slum children were
defined as those attending Clinics A and B, and non-
slum children were those attending Clinic C.
Data collection
The following variables were recorded: reason for visit
to the hospital, date of birth of patient, sex of patient,
household income, home address, whether in school
and where, whether in daycare and where, total number
of people living in house, number of children 15 years
or younger in household, whether had sore throat in
past six months, level of education of mother, level of
education of father, and co-morbidities.
Laboratory Sample Isolation and Identification
Swab cultures were obtained from the pharynx of the
study children following a standard protocol. All study
technicians were observed periodically at the clinic sites
for proper and consistent swabbing technique. A sterile
cotton swab tip was applied to the posterior pharynx
and tonsils, as recommended by the Infectious Disease
Society of America (IDSA) [21]. The swabs were imme-
diately placed in Stuart transport medium, transported
to the laboratory and plated the same day of collection
on 5% sheep blood agar. The plates were incubated at
37°C for 24 - 48 h with 5% CO2. Streptococci were
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phology, and the catalase test. Carbohydrate group iden-
tification (Groups A, B, C, F, G) was performed by
positive latex agglutination (Remel PathoDx Strep
Grouping Latex Test Kit, Remel, Lenexa, KS, USA).
Pure culture samples were stored in 5% glycerol at
-80°C until further use.
emm typing
emm-typing of all isolates were performed as described
by the Center for Disease Control and Prevention
(CDC) protocol http://www.cdc.gov/ncidod/biotech/
strep/protocol_emm-type.htm.
Statistical Analysis
Analyses were conducted by STATA 11.0 (Stata Inc.,
College Station, Texas). Categorical variables were
compared with the chi-square test. Student’st - t e s ta n d
ANOVA were used to compare means, and multivari-
able logistic regression was used to evaluate the asso-
ciation between specific emm types and case status
while controlling for covariates. Models were restricted
to those children with culture-positive GAS. Simpson’s
index of diversity was used to calculate the variation of
the number of emm types of GAS isolates by clinic or
by case status [22]. Higher index measures represent
greater diversity of emm types, since the method calcu-
lates the probability that any two randomly selected
isolates from the same population will be of different
emm types. Confidence intervals (CI’s, 95%) for the
diversity index measures were calculated as previously
described [23].
Results
Demographic and clinical characteristics
Between April 17, 2008 and October 31, 2008, 2194
children aged 3-15 years (759 in Clinic A, 518 in Clinic
B, 917 in Clinic C), who met the eligibility criteria, were
identified from the three study clinics. Of 2181 children
with data on case status, 624 (28.6%) came with a com-
plaint of sore throat (cases), and 1557 (71.4%) came for
other illnesses. The distribution of reasons for visit
among the controls was comparable across the three
hospitals (data not shown).
The mean age of all the study children differed
between slum (7.2 years) and non-slum residents (7.8
years)(p < 0.001, Table 1). The sex distribution did not
differ between slum and non-slum populations. One
minimal monthly salary (MS) or less (equivalent to US
$246.10 as of April 2008) was reported by 648 (53.8%)
of 1205 slum households, and 37 (4.3%) of 870 non-
slum households (P < .001). Salary was positively corre-
lated with level of education in this study. The mean
number of members per household in the slum popula-
tion (4.5) was greater than that in the non-slum
population (4.0) (p < .001). The mean number of chil-
dren <15 years per household was greater in the slum
population (2.0 persons) than that in the non-slum
population (1.6 persons) (p < .001).
The difference in mean age between cases (7.4 years)
and controls (7.5 years) or between patients who tested
positive for GAS (7.6 years) or negative for GAS (7.5)
were not significant, both in the total study population,
and when stratified by slum status.
Microbiologic studies
In total, 529 Streptococcus isolates (groups A-G) from
2194 children were obtained (Table 1). Of these, 254
(48%) were GAS (Table 2). Of 253 GAS isolates (1 iso-
late missing case/control status), 125 (8%) were from
controls and 128 (20.5%) were obtained from cases (p <
.001). The proportion of cases who tested culture posi-
tive for GAS differed by slum (23.1%) vs. non-slum
clinic subjects (17.4%), which approached statistical sig-
nificance (p = 0.08). The proportion of controls that
tested positive for GAS did not differ between slum vs.
non-slum children (7.8% vs. 8.2%).
emm diversity
Of 254 GAS isolates, 238 yielded interpretable emm
sequences. These 238 isolates represented 61 unique
emm types. In the non-slum population, 94 isolates
comprised 36 distinct emm types (38.3%). In the slum
population, 144 isolates comprised 53 distinct emm
types (36.8%). Between these two groups, the proportion
of unique emm types did not differ (p = 0.81). The pro-
portion of unique emm types was higher for carriage
isolates than for sore throat cases in the slum popula-
tion, but this finding did not reach statistical signifi-
cance (p = 0.11) (Table 3).
Simpson’s diversity index for all the emm types was
96% (94%-97%). The index was 92% (89%-96%) for the
non-slum GAS emm types, and 97% (96%-98%) for slum
emm types. The CI’s for slum vs. non-slum only overlap
at the lower bound estimate for slum, and the upper
bound estimate of non-slum. Separating the two slum
communities, the Simpson’s diversity index was 96%
(94%-98%) for Clinic A, and 97% (96%-99%) for Clinic
B. For both slum and non-slum populations, the diver-
sity index was lower for cases than for controls [non-
slum: 90% vs. 93%; slum 96% vs. 98%] (Table 3).
In both slum and non-slum populations, emm12.0 was
the predominant type, followed by emm1.0 (Figure 1).
However, in the non-slum population, 20 (21.3%) of 94
isolates were emm12.0, whereas in the slum population,
18 (12.5%) of 144 isolates were emm12.0 (p = 0.07).
emm1.0 was the second most prevalent emm type in
both populations, and also constituted a larger propor-
tion of non-slum isolates. In the non-slum population,
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Page 3 of 8Table 1 Demographic characteristics and streptococcal group distributions of children attending slum and non-slum
clinics
Total Population (n = 2194) Non-slum
a (n = 917) Slum
b (n = 1277)
N N p-value
Cases 624 915 287 1266 337 –
Controls 1557 915 628 1266 929 –
Mean Age in years (95%CI) 7.5 (7.3-7.6) 917 7.8 (7.6-8.1) 1277 7.2 (7.1-7.4) <.001
Sex 1.0
Female 1060 917 443 1277 617
Male 1134 917 474 1277 660
Monthly salary 870 1205 <.001
≤415 685 37 648
416-830 550 161 389
831-1660 336 204 132
1661-2490 195 173 22
≥2491 309 295 14
Mean # people/house (95%CI) 4.3 (4.2-4.3) 917 4.0 (3.9-4.1) 1275 4.5 (4.4-4.6) <.001
Mean # people ≤ 15 yrs./house (95%CI) 1.8 (1.8-1.9) 917 1.6 (1.5-1.6) 1276 2.0 (2.0-2.1) <.001
Group A 254 917 99 1277 155 0.33
Group B 34 917 24 1277 10 .001
Group C 57 917 30 1277 27 0.09
Group F 51 917 24 1277 27 0.44
Group G 133 917 46 1277 87 0.08
aIncludes all children from Clinic C
bIncludes all children from Clinics A and B
N: total number with available response
Table 2 Demographic and streptococcal group distributions, by sore throat and carriage in slum versus non-slum
children
Non-slum (n = 915)
a Slum (n = 1266)
b
Case (%)
c Control (%)
c p-value Case (%) Control (%) p-value
287 (31.4) 628 (68.6) 337 (26.6) 929 (73.4)
Mean Age (95% CI) 7.8 (7.3-8.2) 7.9 (7.6-8.1) 0.67 7.2 (6.8-7.5) 7.3 (7.1-7.5) 0.57
Male 139 (48.4) 335 (53.3) 0.17 146 (43.3) 508 (54.7) <.001
Monthly Salary N = 274 N = 594 0.02 N = 312 N = 882 .75
≤415 11 (4.0) 26 (4.4) 178 (57.1) 468 (53.1)
416-830 38 (13.9) 123 (20.7) 91 (29.2) 291 (33.0)
831-1660 58 (21.2) 145 (24.4) 34 (10.9) 96 (10.9)
1661-2490 55 (20.1) 117 (19.7) 5 (1.6) 17 (1.9)
≥2491 112 (40.9) 183 (30.8) 4 (1.3) 10 (1.1)
Mean # persons per household (95% CI) 4.0 (3.9-4.2) 4.0 (3.9-4.1) 0.96 4.5 (4.3-4.8) 4.4 (4.3-4.5) 0.27
Mean # < 15 yrs. per household (95% CI) 1.5 (1.5-1.6) 1.6 (1.6-1.7) 0.16 2.1 (2.0-2.3) 2.0 (1.9-2.1) 0.06
Group A 50 (17.4) 49 (7.8) <.001 78 (23.1) 76 (8.2) <.001
Group B 7 (2.4) 17 (2.7) 0.81 4 (1.1) 6 (0.6) 0.34
Group C 8 (2.8) 22 (3.5) 0.57 6 (1.8) 21 (2.3) 0.60
Group F 6 (2.1) 18 (2.9) 0.50 7 (2.1) 20 (2.2) 0.93
Group G 8 (2.8) 38 (6.1) 0.04 17 (5.0) 70 (7.5) 0.12
No isolate 208 (72.5) 475 (75.6) 0.17 225 (66.8) 736 (79.2) <.001
a Includes all patients from Clinic C. Case/control status missing for 2 study participants
b Includes all patients from Clinics A and B. Case/control status missing for 11 study participants
c Case = sore throat; control = carriage
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Page 4 of 8Table 3 Diversity of emm types in non-slum versus slum populations
Simpson’s Diversity Index CI Number of Unique emm Types Number of Isolates Proportion Unique
All 0.95 (0.94-0.97) 61 238 26.1%
Non-Slum 0.92 (0.89-0.96) 36 94 38.3%
Case 0.90 (0.84-0.97) 24 49 49.0%
Carriage 0.93 (0.88-0.97) 21 45 46.7%
Slum 0.97 (0.96-0.98) 53 144 36.8%
Case 0.96 (0.94-0.98) 34 74 45.9%
Carriage 0.98 (0.97-0.99) 41 69 59.4%
Figure 1 Proportion of the most common emm types in non-slum (A) and slum (B) populations. Only emm types represented by more
than one isolate are included in the graphs. Bars in red indicate emm types included in the 26-valent vaccine. Blue bars indicate emm types not
included in the vaccine.
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Page 5 of 814 (14.9%) of 94 isolates were emm1.0, and in the slum
population, emm1.0 constituted 9 (6.3%) of 144 isolates
(p = 0.03). The three most predominant emm types con-
stituted a much larger proportion of isolates in the non-
slum population as compared with the slum population
(41.5% vs. 24.3%)(p = 0.005), suggesting that GAS diver-
sification was greater in the slum population.
Only 7 emm types 12.0 (n = 38), 1.0 (n = 23), st2904.1
(n = 13), 66.0 (n = 12), 87.0 (n = 9), 49.3 (n = 8), and
27G.0 (n = 8) comprised 46.6% of the total. There were
22 emm types that were represented by only a single
isolate. In total, 25 distinct emm types were detected
only in slum children, compared with only 8 emm types
which were found only in non-slum children. emm
types which were represented by only one isolate were
more likely to be found in children 10 years or older,
than in those 9 and younger, which approached statisti-
cal significance (p = 0.08).
emm type and case status
Three emm types were significantly associated, confer-
ring either risk or protection, with sore throat. Of those
who tested positive for GAS, those with emm12.0 (n =
38) had 2.2 times the odds of having sore throat com-
pared with those with a different emm type (p = 0.04),
after adjusting for age, income and number of children
less than 15 years of age in the household (Table 4). For
those patients with emm66.0 (n = 12), the odds of sore
throat were 8.7 times that of sore throat with other
emm types in the multivariable model (p = 0.04). Inter-
estingly, an inverse relationship was seen for emm27G.0
(n = 8), where those with this emm type had 0.1 times
the odds of sore throat compared with other emm types
in the multivariable model (p = 0.07).
Vaccine Coverage
In this study, 100 (42.0%) of the 238 emm typed isolates,
and 15 (24.6%) of the 61 emm types would be covered
by the 26-valent M-protein-based GAS vaccine,
assuming cross-immunity between type 1.2 and subtype
1.25, between type 101 and subtype 101.1, and between
type 33.0 and subtype 33.1 [12]. Stratifying by popula-
tions, 45 (47.9%) of 94 isolates and 10 (27.8%) of 36
emm types from non-slum children would be covered
by the vaccine. In the slum, the coverage for isolates
would be 52 (36.1%) of 144 isolates, and 11 (20.8%) of
53 emm types.
In children presenting with sore throat, 55 (44.7%) of
123 emm typed isolates, and 13 (30.2%) of 43 emm
types would be covered by the current 26-valent M-pro-
tein-based GAS vaccine. In the non-slum population, 25
(51.0%) of 49 emm typed isolates, and 8 (33.3%) of 24
emm types would be covered. In the slum population,
32 (43.2%) of 74 emm typed isolates, and 10 (29.4%) of
34 emm types would be covered by the vaccine.
Discussion
In Salvador, Brazil we found significant differences in
emm type diversity among GAS isolates obtained from
different populations in the same city. The diversity
index was significantly higher among GAS isolates from
children residing in slum communities (97%) compared
to those living in wealthier neighborhoods (92%). In
fact, the diversity index of the non-slum GAS isolates
was closer to that of emm types reported from high
income countries (92%) than to those found in the slum
populations of the same city Salvador [19]. This study
suggests that GAS strain diversification may be influ-
enced by local factors. Such factors may include crowd-
ing which is more prevalent in slum communities.
Crowding may facilitate increased transmission opportu-
nities and possible horizontal gene transfers that contri-
bute to strain diversification. For socioeconomic
reasons, slum residents are also less likely to undergo
antibiotic treatment for sore throat. Our data found sig-
nificant differences in household density, type of health
Table 4 Common emm types and association with sore throat or carriage, among GAS culture-positive (n = 253)
patients
Emm
Type
N (%) Case (n = 128) Control (n = 125) Crude
OR
p-
value
95%
CI
OR
a p-
value
95%
CI
Multivariable
OR
b
p-
value
95%
CI
12.0 38
(15.0)
25 13 2.09 0.05 1.0-4.3 2.12 0.04 1.0-4.4 2.21 0.04 1.1-4.7
1.0 23 (9.1) 11 12 0.89 0.78 .4-2.1 0.88 0.77 .4-2.1 0.84 0.69 .4-2.0
st2904.1 13 (5.1) 7 6 1.15 0.81 .4-3.5 1.15 0.80 .4-3.5 1.13 0.83 .4-3.5
66.0 12 (4.7) 9 2 4.65 0.05 1.0-
22.0
4.64 0.05 1.0-
21.9
8.70 0.04 1.1-
70.5
87.0 9 (3.6) 5 4 1.23 0.76 .3-4.7 1.22 0.77 .4-7.1 1.29 0.71 .3-5.0
49.3 8 (3.2) 5 3 1.65 0.5 .4-7.1 1.66 0.50 .4-7.1 1.13 0.88 .2-5.8
27G.0 8 (3.2) 1 7 0.13 0.06 .0-1.1 0.13 0.06 .0-1.1 0.14 0.07 .0-1.1
Unique 22 (8.7) 10 12 0.80 0.61 .3-1.9 0.79 0.61 .3-1.9 0.65 0.39 .3-1.7
aAdjusted for age
bAdjusted for age, income, number <15 yrs. in household
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slum communities (Table 1).
In addition to emm type differences in GAS strains
across high-income vs. low-income populations in the
same city, we found certain emm types to be over or
under-represented among children with sore throat
[emm66.0 (OR = 8.7), emm12.0 (OR = 2.2), emm27G.0
(OR = 0.1)]. Furthermore, we were able to identify clini-
cally relevant strains that comprised less than 5%
(emm66.0) and less than 3% (emm27G.0) of the sample
population. Further laboratory studies are warranted to
determine why certain emm types predominate in clini-
cal cases (emm66.0, emm12.0) or are inversely asso-
ciated with sore throat (emm27G.0).
A vaccine against GAS will have substantial benefits
worldwide. However, the impact on disease reduction
could vary by region depending on the vaccine composi-
tion. Currently, the only vaccine to complete phase I/II
trials is a 26-valent recombinant M protein vaccine
[12,24]. In our study, only 42% of the total isolates, and
44.7% of isolates from cases, would be covered by the
26-valent M-protein-based GAS vaccine. Furthermore,
the coverage of the 26-valent vaccine in all slum (36%)
versus non-slum (48%) isolates would not be equal even
within the same city.
Conclusions
This study suggests that local demographic and socioe-
conomic factors may contribute to the diversification of
GAS emm types, and that distinct bacterial population
distribution occurs between different neighborhoods
separated by 11-32 km in the same city. This distinction
might be particularly pronounced in cities with slums.
We note that it is not simply poverty itself that deter-
mines this difference [25,26]. As the world expands
toward the projected population size of two billion slum
residents in less than 30 years, it will be essential to bet-
ter elucidate the slum structural dynamics which contri-
bute to major differences in disease outcomes and
vaccine coverage [20].
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